Drugs / Lopinavir/ritonavir
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01641367 Background | Feb 2013 → Nov 2016 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-02-27 | AbbVie | AbbVie Statement on Coronavirus and lopinavir/ritonavir abbvie.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01641367 ↗ |